FDA Approves Luspatercept-aamt for Anemia in Patients with Beta Thalassemia
Nov 08
2019
The Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corp.) for treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.